Vimseltinib (Cat No.:I015466) is a potent, orally bioavailable small-molecule inhibitor of colony-stimulating factor 1 receptor (CSF1R), a tyrosine kinase regulating macrophage survival and proliferation. By selectively blocking CSF1R signaling, vimseltinib depletes tumor-associated macrophages (TAMs), which are key mediators of immune suppression and tumor progression. It is under clinical development for tenosynovial giant cell tumor (TGCT) and other cancers driven by CSF1R activity. Vimseltinib provides a promising therapeutic strategy in oncology and immunology, offering targeted modulation of the tumor microenvironment to enhance treatment outcomes.